Myriad Genetics: Jerry Lanchbury, Dale Muzzey, Kirsten Timms

Myriad Genetics this week announced the retirement of Jerry Lanchbury as its CSO after nearly two decades at the company. Since he joined Myriad in 2002, he has led efforts to gain regulatory approval for the company's companion diagnostics, BRACAnalysis CDx and myChoice CDx; improve hereditary cancer risk score determinations by developing a polygenic breast cancer risk score for all ancestries; and develop Myriad's Prolaris Prostate Cancer Test. Lanchbury will continue to advise Myriad through the end of Q1 2022. The company is searching nationally for a permanent CSO.

In the interim, Dale Muzzey, formerly the VP of bioinformatics, who Myriad recently promoted to senior VP for R&D, will serve as CSO. Myriad also announced that Kirsten Timms, former VP of biomarker discovery, is now a senior VP, and will work on expanding the capabilities of MyChoice CDx in her new role.